Clinigen and Cumberland collaborate in mutual market access deal

By Dan Stanton

- Last updated on GMT

Clinigen and Cumberland collaborate in mutual market access deal

Related tags Pharmacology Medicine

UK-based Clinigen and US-based Cumberland Pharmaceuticals have struck a deal to market each others products outside their respective countries.

Cumberland Pharmaceuticals is a Nashville, Tennessee-based specialty pharma firm with a portfolio of products including acetylcysteine for the treatment of acetaminophen poisoning, and an ibuprofen injection to manage pain available in the US.

Clinigen, meanwhile, is a UK-based firm which markets its own portfolio of niche pharmaceuticals, on top of supplying commercial medicines for clinical trials.

In the accord announced today, both firms will be marketing, promoting and distributing each other’s portfolios in their home markets.

“A key strategic initiative this year has been to develop our Group's global distribution footprint,”​ said Clinigen’s CEO Peter George. “The US is a particular area of focus where we are looking to initiate a long term strategic partnership and Cumberland was a natural fit as a partner.

Working together is a logical move for both companies as we will mutually benefit from each other's distribution expertise and capabilities in our respective regions,” ​he said, while Cumberland’s CEO AJ Kazimi added in a statement the deal “creates a new growth driver for both companies that builds on our strengths.”

Earlier this year, Clinigen was selected by AstraZeneca​ for its global access programme (GAP) to provide access for the investigational antibiotic CAZ-AVI to eligible patients outside the US and Canada.

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Follow us

Webinars

Headlines